Autolus Therapeutics (NASDAQ:AUTL) Stock Rated Buy in New Coverage at HC Wainwright

Equities research analysts at HC Wainwright assumed coverage on shares of Autolus Therapeutics (NASDAQ:AUTL) in a report released on Monday, Benzinga reports. The brokerage set a “buy” rating on the stock.

Several other equities research analysts have also recently weighed in on AUTL. Weiss Ratings upgraded Autolus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. Wall Street Zen raised Autolus Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, August 16th. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $10.00.

Autolus Therapeutics Stock Performance

Shares of AUTL opened at $1.52 on Monday. The stock has a market capitalization of $404.57 million, a P/E ratio of -1.43 and a beta of 2.15. The company has a quick ratio of 4.40, a current ratio of 4.89 and a debt-to-equity ratio of 1.04. The firm has a fifty day simple moving average of $1.91 and a two-hundred day simple moving average of $1.67. Autolus Therapeutics has a twelve month low of $1.18 and a twelve month high of $2.58.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.06. The firm had revenue of $45.69 million for the quarter, compared to analysts’ expectations of $38.56 million. Autolus Therapeutics had a negative net margin of 238.66% and a negative return on equity of 178.66%. On average, research analysts anticipate that Autolus Therapeutics will post -0.76 EPS for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Syncona Portfolio Ltd purchased a new position in Autolus Therapeutics during the second quarter valued at $26,625,152. Cetera Investment Advisers grew its position in shares of Autolus Therapeutics by 2.7% in the 1st quarter. Cetera Investment Advisers now owns 1,129,074 shares of the company’s stock worth $1,558,000 after buying an additional 29,324 shares during the period. Alphabet Inc. bought a new position in shares of Autolus Therapeutics in the 2nd quarter worth about $1,117,000. Hennion & Walsh Asset Management Inc. increased its stake in shares of Autolus Therapeutics by 2.5% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 451,403 shares of the company’s stock worth $722,000 after acquiring an additional 11,197 shares in the last quarter. Finally, R Squared Ltd lifted its position in Autolus Therapeutics by 48.4% during the 1st quarter. R Squared Ltd now owns 39,575 shares of the company’s stock valued at $55,000 after acquiring an additional 12,915 shares during the period. 72.83% of the stock is owned by hedge funds and other institutional investors.

About Autolus Therapeutics

Autolus Therapeutics plc is a biopharmaceutical company focused on developing and commercializing programmed T-cell therapies for cancer. The company’s approach is designed to engineer T cells to recognize and eliminate malignant cells while incorporating features intended to improve activity, persistence and safety.

Its lead product, obecabtagene autoleucel, is an autologous CAR T-cell therapy marketed in the United States under the brand name Aucatzyl. It is used to treat adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.